After a median follow-up of 32.2 months, atezolizumab treatment improved disease-free survival compared with best supportive care in 495 patients in the stage II–IIIA population whose tumors expressed PD-L1 on  ≥ 1% of tumor cells (HR 0.66; 95% CI 0.50–0.88; p = 0.0039) and in all patients in the stage II–IIIA population (HR 0.79; 0.64–0.96; p = 0.020). Here, CD274 is linked to neoplasm.